From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 4-15

  Moghaddam, Bita ^a   Javitt, Daniel ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antipsychotic drugs; cognition; dopamine; NMDA receptors

Indexed keywords

ACETYLCYSTEINE; AMPA RECEPTOR; CLOZAPINE; CYCLOSERINE; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; GLUTAMIC ACID; GLUTATHIONE; GLYCINE; GLYCINE TRANSPORTER; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SARCOSINE;

ACUTE SCHIZOPHRENIA; AMINO ACID METABOLISM; BRAIN NERVE CELL; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC TRANSMISSION; HUMAN; HYPOTHESIS; INTERNEURON; NEPHROTOXICITY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC INHIBITION; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; STEREOTYPY;

GLUTAMIC ACID; HUMANS; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84856120944     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.181     Document Type: Review

References (114)

1. Abbott A (2010). Schizophrenia: the drug deadlock. Nature 468: 158-159.
2. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554. (Pubitemid 28311969)
3. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ et al (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40: 827-834. (Pubitemid 351913655)
4. Anderson S, Volk D et al (1996). Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophr Res 19: 111-119. (Pubitemid 26180479)
5. Arai AC, Kessler M (2007). Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 8: 583-602. (Pubitemid 46785059)
6. Ardekani BA, Bappal A et al (2005). Brain morphometry using diffusion-weighted magnetic resonance imaging: application to schizophrenia. Neuroreport 16: 1455-1459. (Pubitemid 41805663)
7. Battaglia G, Monn JA et al (1997). In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161-164. (Pubitemid 27316071)
8. Begni S, Moraschi S et al (2003). Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol Psychiatry 53: 617-619. (Pubitemid 36385063)
9. Bergeron R, Meyer T et al (1998). Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95: 15730-15734. (Pubitemid 29018768)
10. Berk M, Copolov D et al (2008). N-acetyl cysteine as a glutathione precursor for schizophreniaFa double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64: 361-368.
11. Breier A, Malhotra AK et al (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811. (Pubitemid 27230103)
12. Bridges TM, LeBois EP et al (2010). The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect 23: 229-240.
13. Buchanan RW, Javitt DC et al (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164: 1593-1602. (Pubitemid 350069740)
14. Buzsaki G, Geisler C et al (2004). Interneuron diversity series: circuit complexity and axon wiring economy of cortical interneurons. Trends Neurosci 27: 186-193. (Pubitemid 38376405)
15. Carlsson M, Carlsson A (1989). The NMDA antagonist MK-801 causes marked locomotor stimulation in monamine-depleted mice. J Neural Transm 75: 221-226. (Pubitemid 19039948)
16. Cartmell J, Monn JA et al (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170. (Pubitemid 29451586)
17. Cartmell J, Monn JA et al (2000). The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400: 221-224. (Pubitemid 30438730)
18. Chen GM, Weston JK (1960). The analgesic and anesthetic effect of 1-(1-phenylcyclohexyl) piperidine HCl on the monkey. Anesth Analg 39: 132-137.
19. Chen L, Muhlhauser M et al (2003). Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89: 691-703. (Pubitemid 36206118)
20. Conn PJ, Lindsley CW et al (2009). Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30: 25-31.
21. Corlew R, Brasier DJ et al (2008). Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity. Neuroscientist 14: 609-625.
22. Creese I, Burt D et al (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483.
23. Csicsvari J, Hirase H et al (1998). Reliability and state dependence of pyramidal cell-interneuron synapses in the hippocampus: an ensemble approach in the behaving rat. Neuron 21: 179-189. (Pubitemid 28355702)
24. Dodd S, Dean O et al (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8: 1955-1962.
25. Ehrlichman RS, Maxwell CR et al (2008). Deviance-elicited changes in eventrelated potentials are attenuated by ketamine in mice. J Cogn Neurosci 20: 1403-1414.
26. Foussias G, Remington G (2010). Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 55: 117-125.
27. Gaisler-Salomon I, Miller GM et al (2009). Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacol 34: 2305-2322.
28. Geyer MA, Krebs-Thomson K et al (1999b). The effects of M100907 on pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology 21: S134-S142.
29. Goff DC, Lamberti JS et al (2008). A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacol 33: 465-472.
30. Goldberg T, Weinberger D (1996). Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 57(Suppl 9): 62-65. (Pubitemid 26327760)
31. Goldberg TE, David A et al (2003). Neurocognitive deficits in schizophrenia. Schizophrenia. S. R. Hirsch and D. R. Weinberger. Blackwell Publishing Company: Oxford, 168-184.
32. Green MF, Nuechterlein KH (1999). Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 25: 309-319. (Pubitemid 29272507)
33. Gysin R, Kraftsik R et al (2007). Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 104: 16621-16626. (Pubitemid 350211066)
34. Hashimoto K, Fujita Y et al (2009). Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 65: 1103-1106.
35. Heekeren K, Daumann J et al (2008). Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 199: 77-88.
36. Heresco-Levy U, Javitt DC et al (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29-36. (Pubitemid 29055047)
37. Homayoun H, Jackson ME et al (2005). Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93: 1989-2001. (Pubitemid 40404399)
38. Homayoun H, Moghaddam B (2007a). Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry 61: 679-687. (Pubitemid 46328858)
39. Homayoun H, Moghaddam B (2007b). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496-11500. (Pubitemid 350006886)
40. Jackson M, Homayoun H et al (2004). NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101: 6391-6396.
41. Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9: 984-997, 979. (Pubitemid 39524288)
42. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-Daspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78: 69-108.
43. Javitt DC (2009a). Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12: 468-478.
44. Recent review of the glycine transport inhibitor approach. Javitt DC (2009b). When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol 5: 249-275.
45. Javitt DC, Balla A et al (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29: 300-307. (Pubitemid 38175148)
46. Javitt DC, Balla A et al (1999). A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45: 668-679. (Pubitemid 29170498)
47. Javitt DC, Doneshka P et al (1993). Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 33: 513-519. (Pubitemid 23167217)
48. Javitt DC, Frusciante M (1997). Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology 129: 96-98. (Pubitemid 27037457)
49. Javitt DC, Jotkowitz A et al (1987). Non-competitive regulation of phencyclidine/sigma-receptors by the N-methyl-D-aspartate receptor antagonist D-(-)-2-amino-5-phosphonovaleric acid. Neurosci Lett 78: 193-198. (Pubitemid 17095698)
50. Javitt DC, Steinschneider M et al (1996). Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA 93: 11962-11967. (Pubitemid 26347231)
51. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
52. Javitt DC, Zylberman I et al (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1236. (Pubitemid 24240973)
53. Kim J, Kornhuber H et al (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379-382. (Pubitemid 11160082)
54. Kinon BJ, Zhang L et al (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355.
55. Kirkpatrick B, Fenton WS et al (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214-219.
56. Konno R, Hamase K et al (2010). Mutant mice and rats lacking D-amino acid oxidase. Chem Biodiversity 7: 1450-1458.
57. Kopec K, Flood DG et al (2010). Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol 80: 1407-1417.
58. Kristiansen LV, Huerta I et al (2007). NMDA receptors and schizophrenia. Curr Opin Pharmacol 7: 48-55.
59. Krystal J, Karper L et al (1995). Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humans. Schizophr Res 15: 156a.
60. Krystal JH, Abi-Saab W et al (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303-309. (Pubitemid 40576718)
61. Krystal JH, Karper LP et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214. (Pubitemid 24081509)
62. Labrie V, Roder JC (2009). The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 34: 351-372.
63. Lane HY, Chang YC et al (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62: 1196-1204.
64. Lane HY, Lin CH et al (2010). A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 13: 451-460.
65. Lane HY, Liu YC et al (2008). Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 63: 9-12.
66. Larsen RS, Corlew RJ, Henson MA, Roberts AC, Mishina M, Watanabe M et al (2011). NR3A-containing NMDARs promote neurotransmitter release and spike timing-dependent plasticity. Nat Neurosci 14: 338-344.
67. Lecourtier L, Homayoun H et al (2007). Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 62: 739-746. (Pubitemid 47374648)
68. Lesh TA, Niendam TA et al (2011). Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacol 36: 316-338.
69. Lieberman JA, Stroup TS et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. (Pubitemid 41345943)
70. Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179: 54-67. (Pubitemid 40576692)
71. Liu F, Grauer S et al (2008). ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4- fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 327: 827-839.
72. Liu J, Moghaddam B (1995). Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Ther 274: 1209-1215.
73. Lorrain DS, Baccei CS et al (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II| selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706. (Pubitemid 36263162)
74. Luby ED, Gottlieb JS et al (1962). Model psychoses and schizophrenia. Am J Psychiatry 119: 61-67.
75. Maccaferri G, Dingledine R (2002). Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 22: 5462-5472. (Pubitemid 35386468)
76. Marder SR (1999). Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies. Neuropharmacology 21: S117-S121.
77. Marek GJ, Behl B et al (2010). Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77: 317-326.
78. Martucci L, Wong AH et al (2006). N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr Res 84: 214-221.
79. Marx CE, Keefe RS et al (2009). Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacol 34: 1885-1903.
80. Matute C, Melone M et al (2005). Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49: 451-455. (Pubitemid 40222921)
81. Meltzer HY, Arvanitis L et al (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984. (Pubitemid 38735983)
82. Moghaddam B (2003). Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881-884. (Pubitemid 37522046)
83. Moghaddam B (2004). Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174: 39-44. (Pubitemid 38925089)
84. Moghaddam B, Adams B (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352. (Pubitemid 28406826)
85. Moghaddam B, Adams B et al (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927. (Pubitemid 27155025)
86. Muir J, Everitt B et al (1995). Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology 118: 82-92.
87. Naatanen R, Kahkonen S (2009). Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmaco 1/12: 125-135.
88. Omdal R, Brokstad K et al (2005). Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 12: 392-398. (Pubitemid 40524182)
89. Parmentier-Batteur S, OBrien JA, Doran S, Nguyen SJ, Flick RB, Uslaner JM (2010). Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology (e-pub ahead of print 26 November 2010).
90. Patil ST, Zhang L et al (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107. (Pubitemid 47517511)
91. Preskorn SH, Baker B et al (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28: 631-637.
92. Qin S, Zhao X et al (2005). An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 13: 807-814. (Pubitemid 40946078)
93. Ritsner MS (2010). Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci Ther 16: 32-44.
94. Rodriguez-Santiago B, Brunet A et al (2010). Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. Mol Psychiatry 15: 1023-1033.
95. Schoepp DD, Johnson BG et al (1997). LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36: 1-11. (Pubitemid 27115837)
96. Seeman P (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clini Schizophr Relat Psychoses 4: 56-73.
97. Seeman P, Chau-Wong M et al (1975). Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72: 4376-4380.
98. Shimazaki T, Kaku A, Chaki S (2010). D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 209: 263-270.
99. Shih AY, Erb H et al (2006). Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 26: 10514-10523. (Pubitemid 44564602)
100. Simpson EH, Kellendonk C et al (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65: 585-596.
101. Spear N, Gadient RA, Wilkins DE, Do M, Smith JS, Zeller KL (2010). Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol 659: 146-154.
102. Tikhonravov D, Neuvonen T et al (2008). Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res 1203: 97-102.
103. Tsai G, Lane HY et al (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55: 452-456. (Pubitemid 38338531)
104. Tsai GE, Lin PY (2010). Strategies to enhance N-methyl-D-aspartate receptormediated neurotransmission in schizophrenia, a critical review and metaanalysis. Curr Pharm Des 16: 522-537.
105. Tuominen H, Tiihonen J et al (2005). Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72: 225-234. (Pubitemid 39550993)
106. Umbricht D, Schmid L et al (2000). Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57: 1139-1147.
107. Umbricht D, Yoo K et al (2010). Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 35: S320-S321.
108. Vollenweider FX, Leenders KL et al (1997). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25-38. (Pubitemid 27139717)
109. Wang H, Westin L et al (2009). Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science 326: 1554-1557.
110. Weiser et al (2008). Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disorders. Biol Psych 63: 602-608. (Pubitemid 351284468)
111. Wolkenberg SE, Sur C (2010). Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. Curr Top Med Chem 10: 170-186.
112. Wonodi I, Schwarcz R (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36: 211-218.
113. Wroblewska B, Lewis DA (2009). Validating novel targets for pharmacological interventions in schizophrenia. Am J Psychiatry 166: 753-756.
114. Zukin SR, Zukin RS (1979). Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 76: 5372-5376. (Pubitemid 10231634)